- Home
- GHI vs DBVT Comparison
GHI vs DBVT Comparison
Compare GHI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- DBVT
- Stock Information
- Founded
- GHI 1998
- DBVT 2002
- Country
- GHI United States
- DBVT France
- Employees
- GHI N/A
- DBVT N/A
- Industry
- GHI Finance: Consumer Services
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GHI Finance
- DBVT Health Care
- Exchange
- GHI Nasdaq
- DBVT Nasdaq
- Market Cap
- GHI 269.5M
- DBVT 239.9M
- IPO Year
- GHI N/A
- DBVT N/A
- Fundamental
- Price
- GHI $12.00
- DBVT $8.35
- Analyst Decision
- GHI Strong Buy
- DBVT Buy
- Analyst Count
- GHI 4
- DBVT 4
- Target Price
- GHI $16.00
- DBVT $14.81
- AVG Volume (30 Days)
- GHI 35.3K
- DBVT 102.2K
- Earning Date
- GHI 05-07-2025
- DBVT 07-29-2025
- Dividend Yield
- GHI 12.33%
- DBVT N/A
- EPS Growth
- GHI N/A
- DBVT N/A
- EPS
- GHI 0.45
- DBVT N/A
- Revenue
- GHI $34,065,322.00
- DBVT $3,497,000.00
- Revenue This Year
- GHI $224.76
- DBVT $1,700.53
- Revenue Next Year
- GHI $5.50
- DBVT $535.67
- P/E Ratio
- GHI $26.81
- DBVT N/A
- Revenue Growth
- GHI N/A
- DBVT N/A
- 52 Week Low
- GHI $10.12
- DBVT $2.21
- 52 Week High
- GHI $15.31
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- GHI 57.03
- DBVT 42.98
- Support Level
- GHI $11.26
- DBVT $8.33
- Resistance Level
- GHI $11.93
- DBVT $9.92
- Average True Range (ATR)
- GHI 0.33
- DBVT 0.92
- MACD
- GHI 0.06
- DBVT -0.32
- Stochastic Oscillator
- GHI 100.00
- DBVT 4.53
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.